{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:39:01Z","timestamp":1791517141640,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00428-023-03520-x","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T02:02:28Z","timestamp":1677808948000},"page":"1011-1019","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma\u00a0variant"],"prefix":"10.1007","volume":"482","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1338-7107","authenticated-orcid":false,"given":"Siba","family":"El Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Gruschkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Schlette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Zahra","family":"Jelloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Fiskus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenya","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beenu","family":"Thakral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil N.","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"3520_CR1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1084\/jem.20131448","volume":"210","author":"G Fabbri","year":"2013","unstructured":"Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, Pasqualucci L, Rabadan R, Dalla-Favera R (2013) Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 210:2273\u20132288","journal-title":"J Exp Med"},{"key":"3520_CR2","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","volume":"131","author":"D Rossi","year":"2018","unstructured":"Rossi D, Spina V, Gaidano G (2018) Biology and treatment of Richter syndrome. Blood 131:2761\u20132772","journal-title":"Blood"},{"key":"3520_CR3","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","volume":"61","author":"Y Ben-Dali","year":"2020","unstructured":"Ben-Dali Y, Hleuhel MH, da Cunha-Bang C, Brieghel C, Poulsen CB, Clasen-Linde E, Bentzen HHN, Frederiksen H, Christiansen I, Nielsen LH, Enggaard L, Helleberg M, Clausen M, Frederiksen M, Pedersen RS, Niemann CU, Andersen MA (2020) Richter\u2019s transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. Leuk Lymphoma 61:1435\u20131444","journal-title":"Leuk Lymphoma"},{"key":"3520_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2019.224121","volume":"105","author":"Y Wang","year":"2020","unstructured":"Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W (2020) Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica 105:765\u2013773","journal-title":"Haematologica"},{"key":"3520_CR5","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","volume":"122","author":"E Chigrinova","year":"2013","unstructured":"Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, Chan WC, Orlandi EM, Lucioni M, Marasca R, Inghirami G et al (2013) Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 122:2673\u20132682","journal-title":"Blood"},{"key":"3520_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679\u2013690","journal-title":"Nat Med"},{"key":"3520_CR7","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W et al (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378:1396\u20131407","journal-title":"N Engl J Med"},{"key":"3520_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, Jiang A, Bagaev A, Plotnikova O, Kotlov N, Johnson CA, Wilson WH, Scott DW, Staudt LM (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37:551\u201368 e14","journal-title":"Cancer Cell"},{"key":"3520_CR9","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1038\/s41379-020-0616-y","volume":"33","author":"S El Hussein","year":"2020","unstructured":"El Hussein S, Shaw KRM, Vega F (2020) Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers. Mod Pathol 33:2422\u20132436","journal-title":"Mod Pathol"},{"key":"3520_CR10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","volume":"30","author":"DM Dorfman","year":"2006","unstructured":"Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ (2006) Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 30:802\u2013810","journal-title":"Am J Surg Pathol"},{"key":"3520_CR11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","volume":"39","author":"L Xerri","year":"2008","unstructured":"Xerri L, Chetaille B, Serriari N, Attias C, Guillaume Y, Arnoulet C, Olive D (2008) Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia. Hum Pathol 39:1050\u20131058","journal-title":"Hum Pathol"},{"key":"3520_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1155\/2010\/404069","volume":"29","author":"S Muenst","year":"2010","unstructured":"Muenst S, Hoeller S, Willi N, Dirnhofera S, Tzankov A (2010) Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers 29:47\u201353","journal-title":"Dis Markers"},{"key":"3520_CR13","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126:2193\u20132201","journal-title":"Blood"},{"key":"3520_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41379-018-0193-5","volume":"32","author":"L Li","year":"2019","unstructured":"Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H et al (2019) PD-1\/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol 32:741\u2013754","journal-title":"Mod Pathol"},{"key":"3520_CR15","doi-asserted-by":"publisher","first-page":"59976","DOI":"10.18632\/oncotarget.11045","volume":"7","author":"W Xing","year":"2016","unstructured":"Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ (2016) PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 7:59976\u201359986","journal-title":"Oncotarget"},{"key":"3520_CR16","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","volume":"129","author":"W Ding","year":"2017","unstructured":"Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN et al (2017) Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129:3419\u20133427","journal-title":"Blood"},{"issue":"22","key":"3520_CR17","doi-asserted-by":"publisher","first-page":"Abstract 59","DOI":"10.1182\/blood.V128.22.59.59","volume":"128","author":"NBS Jain","year":"2016","unstructured":"Jain NBS, Thompson PA et al (2016) Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial [abstract]. Blood 128(22):Abstract 59","journal-title":"Blood"},{"key":"3520_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.15508","volume":"185","author":"KA Rogers","year":"2019","unstructured":"Rogers KA, Huang Y, Dotson E, Lundberg J, Andritsos LA, Awan FT, Woyach JA, Byrd JC (2019) Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. Br J Haematol 185:363\u2013366","journal-title":"Br J Haematol"},{"key":"3520_CR19","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigon MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yagci M, Horowitz NA, Marlton P, Cordoba R et al (2019) Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study. Lancet Haematol 6:e67\u2013e78","journal-title":"Lancet Haematol"},{"key":"3520_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/bjh.15514","volume":"185","author":"A Behdad","year":"2019","unstructured":"Behdad A, Griffin B, Chen YH, Ma S, Kelemen K, Lu X, Chen QC (2019) PD-1 is highly expressed by neoplastic B-cells in Richter transformation. Br J Haematol 185:370\u2013373","journal-title":"Br J Haematol"},{"key":"3520_CR21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","volume":"42","author":"R He","year":"2018","unstructured":"He R, Ding W, Viswanatha DS, Chen D, Shi M, Van Dyke D, Tian S, Dao LN, Parikh SA, Shanafelt TD, Call TG, Ansell SM, Leis JF, Mai M, Hanson CA, Rech KL (2018) PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell Richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness. Am J Surg Pathol 42:843\u2013854","journal-title":"Am J Surg Pathol"},{"key":"3520_CR22","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/bjh.13085","volume":"167","author":"GW Slack","year":"2014","unstructured":"Slack GW, Steidl C, Sehn LH, Gascoyne RD (2014) CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol 167:608\u2013617","journal-title":"Br J Haematol"},{"key":"3520_CR23","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1182\/blood.V122.21.4318.4318","volume":"122","author":"AMB Collie","year":"2013","unstructured":"Collie AMB, Hill BT, Manilich EA, Smith MR (2013) Hsi ED: CD30 immunohistochemical expression in diffuse large B-cell lymphoma is associated with decreased overall survival and the non-germinal center molecular subtype. Blood 122:4318","journal-title":"Blood"},{"key":"3520_CR24","first-page":"1475","volume":"130","author":"G Rassidakis","year":"2017","unstructured":"Rassidakis G, Miao Y, Zhang J, Atsaves V, Kis L, Smedby KE, Li Y, Xu-Monette ZY, Young KH (2017) PD-L1 expression and gene amplification in CD30+ diffuse large B-cell lymphoma (DLBCL): significance of TP53 genetic impact and clinicopathologic characteristics. Blood 130:1475","journal-title":"Blood"},{"key":"3520_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","volume":"121","author":"IH Sahin","year":"2019","unstructured":"Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C (2019) Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer 121:809\u2013818","journal-title":"Br J Cancer"},{"key":"3520_CR26","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/j.clml.2021.12.004","volume":"22","author":"S El Hussein","year":"2022","unstructured":"El Hussein S, Daver N, Liu JL, Kornblau S, Fang H, Konoplev S, Kantarjian H, Khoury JD (2022) Microsatellite instability assessment by immunohistochemistry in acute myeloid leukemia: a reappraisal and review of the literature. Clin Lymphoma Myeloma Leuk 22:e386\u2013ee91","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3520_CR27","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SHCEHN Swerdlow","year":"2017","unstructured":"Swerdlow SHCEHN, Jaffe ES, Pileri SA, Stein H, Thiele J (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th Edition edn. IARC, Lyon, France","edition":"Revised 4th Edi"},{"key":"3520_CR28","doi-asserted-by":"publisher","first-page":"e0126615","DOI":"10.1371\/journal.pone.0126615","volume":"10","author":"X Hao","year":"2015","unstructured":"Hao X, Wei X, Huang F, Wei Y, Zeng H, Xu L, Zhou Q, Feng R (2015) The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. PLoS One 10:e0126615","journal-title":"PLoS One"},{"key":"3520_CR29","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1182\/blood-2017-02-766857","volume":"129","author":"HY Wang","year":"2017","unstructured":"Wang HY (2017) Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma. Blood 129:2592","journal-title":"Blood"},{"key":"3520_CR30","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19:3462\u20133473","journal-title":"Clin Cancer Res"},{"key":"3520_CR31","doi-asserted-by":"publisher","first-page":"44960","DOI":"10.18632\/oncotarget.16680","volume":"8","author":"P Gravelle","year":"2017","unstructured":"Gravelle P, Burroni B, Pericart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournie JJ, Laurent C (2017) Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget 8:44960\u201344975","journal-title":"Oncotarget"},{"key":"3520_CR32","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/his.12882","volume":"68","author":"D Kwon","year":"2016","unstructured":"Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, Kim YA, Kim TM, Heo DS, Kim CW, Jeon YK (2016) Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology 68:1079\u20131089","journal-title":"Histopathology"},{"key":"3520_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/path.5060","volume":"245","author":"MJ Garcia-Barchino","year":"2018","unstructured":"Garcia-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, Robles EF, Roa S, Celay J, Larrayoz M, Rossi D, Gaidano G, Montes-Moreno S, Piris MA, Balanzategui A et al (2018) Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. J Pathol 245:61\u201373","journal-title":"J Pathol"},{"key":"3520_CR34","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","volume":"20","author":"CY Ok","year":"2014","unstructured":"Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W et al (2014) Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 20:2338\u20132349","journal-title":"Clin Cancer Res"},{"key":"3520_CR35","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J et al (2013) CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121:2715\u20132724","journal-title":"Blood"},{"key":"3520_CR36","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1080\/10428194.2016.1256481","volume":"58","author":"NL Bartlett","year":"2017","unstructured":"Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED (2017) Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma 58:1607\u20131616","journal-title":"Leuk Lymphoma"},{"key":"3520_CR37","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","volume":"125","author":"ED Jacobsen","year":"2015","unstructured":"Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL (2015) Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. Blood 125:1394\u20131402","journal-title":"Blood"},{"key":"3520_CR38","doi-asserted-by":"crossref","unstructured":"Budde LE, Halwani A, Yasenchak CA, Farber CM, Burke JM, Fayad LE, Holkova B, Knapp M, Kolibaba KS, Advani RH, Ansell SM, Patel-Donnelly D, Yimer HA, Smith SE, Levy MY, Seetharam M, Belada D, Brooks D, Kingsley EC, Klein LM, Wagner-Johnston N, Ruffner K, Bartlett NL (216) Results of an ongoing phase 2 study of brentuximab vedotin with Rchp as frontline therapy in patients with high-intermediate\/high-risk diffuse large B cell lymphoma (DLBCL). Blood 128:104","DOI":"10.1182\/blood.V128.22.104.104"},{"key":"3520_CR39","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMp1709968","volume":"377","author":"S Lemery","year":"2017","unstructured":"Lemery S, Keegan P, Pazdur R (2017) First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med 377:1409\u20131412","journal-title":"N Engl J Med"},{"key":"3520_CR40","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R (2019) FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25:3753\u20133758","journal-title":"Clin Cancer Res"},{"key":"3520_CR41","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A et al (2015) PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520","journal-title":"N Engl J Med"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-023-03520-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T03:27:01Z","timestamp":1686194821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-023-03520-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3520"],"URL":"https:\/\/doi.org\/10.1007\/s00428-023-03520-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"27 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}